Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) shares barely budged in price Thursday. The Miami-based Telomir, a preclinical-stage biotechnology company developing therapies that target the underlying mechanisms of aging and age-related diseases, today announced new preclinical data revealing that Telomir-1 potently inhibits three key histone demethylase enzymes-JMJD3, FBXL10, and FBXL11-that regulate gene expression through epigenetic mechanisms.
These enzymes are known to influence tumor progression, immune response, metabolic function, and neuroinflammation.
This morning’s news release reports that the study, conducted in collaboration with Eurofins Discovery, provides further clarity on Telomir-1's mechanism of action and supports its continued development as a disease-modifying candidate across multiple therapeutic areas.
Histone demethylases are upstream regulators of epigenetic silencing and activation. Overactivation of these enzymes can result from genetic amplification, chronic inflammation, or stress signals from the tumor microenvironment.
The release goes on to say that these factors can lead to persistent gene silencing or inappropriate activation of disease-driving genes-contributing directly to tumor growth, immune dysfunction, metabolic imbalance, and neuroinflammation.
"This may be one of the most important mechanistic discoveries in Telomir-1's development," said Erez Aminov, CEO of Telomir. "If confirmed through further studies, it could position Telomir-1 as a breakthrough in the effort to address the root causes of age-related diseases."
TELO shares dipped a penny to $1.83.
